Lori Payton reports a stock award at Yarrow Bioscience

By AlphaYouPublished Oct 30, 2026Form 4

Stocks in this disclosure

Reported activity

Payton Lori

Reporting filer

Lori Payton reports a stock award, not an open-market purchase or sale, in Yarrow Bioscience, Inc.. Form 4 filed Oct 30, 2026 lists 1 entry.

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Stock Option (Right to Buy) (derivative)	Payton Lori	2026-10-29	A	Grant or award	99827	0	99,827	1 day	Filed terms security Title: Stock Option (Right to Buy) conversion Or Exercise Price: 20 transaction Date: 2026-10-29 deemed Execution Date: transaction Form Type: 4 transaction Code: A equity Swap Involved: 0 transaction Timeliness: transaction Shares: 99827 transaction Price Per Share: 0 transaction Acquired Disposed Code: A id: F1 expiration Date: 2036-10-29 underlying Security Title: Common Stock underlying Security Shares: 99827 shares Owned Following Transaction: 99827 direct Or Indirect Ownership: D

Owner: Payton Lori
Date: 2026-10-29
Code: A
Action: Grant or award
Quantity: 99827
Price: 0
Following holdings: 99,827
Reporting delay: 1 day
Filed terms and references: Filed terms
security Title: Stock Option (Right to Buy)
conversion Or Exercise Price: 20
transaction Date: 2026-10-29
deemed Execution Date:
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 99827
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
id: F1
expiration Date: 2036-10-29
underlying Security Title: Common Stock
underlying Security Shares: 99827
shares Owned Following Transaction: 99827
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
Payton Lori: Chief Development Officer.
F1: This option represents a right to purchase 99,827 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Prepared automatically from public filing data. Report a correction.